Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells 2,368 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,368 shares of Nurix Therapeutics stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $57,542.40. Following the transaction, the chief financial officer now directly owns 37,270 shares of the company’s stock, valued at approximately $905,661. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Monday, August 26th, Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00.
• On Thursday, August 1st, Houte Hans Van sold 3,477 shares of Nurix Therapeutics stock. The stock was sold at an average price of $21.45, for a total value of $74,581.65.

Nurix Therapeutics Trading Down 4.5 %

Shares of NRIX stock opened at $24.07 on Thursday. Nurix Therapeutics, Inc. has a 12-month low of $4.96 and a 12-month high of $27.60. The stock has a market capitalization of $1.71 billion, a P/E ratio of -8.27 and a beta of 2.22. The firm’s 50 day moving average is $24.18 and its 200 day moving average is $20.17.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. As a group, equities analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC lifted its stake in shares of Nurix Therapeutics by 576.7% in the 1st quarter. Acadian Asset Management LLC now owns 160,293 shares of the company’s stock worth $2,355,000 after purchasing an additional 136,606 shares during the period. SG Americas Securities LLC raised its position in Nurix Therapeutics by 365.0% in the second quarter. SG Americas Securities LLC now owns 103,199 shares of the company’s stock worth $2,154,000 after acquiring an additional 81,005 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Nurix Therapeutics by 80.7% during the 2nd quarter. Renaissance Technologies LLC now owns 324,000 shares of the company’s stock worth $6,762,000 after acquiring an additional 144,700 shares during the last quarter. TD Asset Management Inc bought a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at $593,000. Finally, Candriam S.C.A. increased its stake in shares of Nurix Therapeutics by 30.5% in the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock worth $24,297,000 after purchasing an additional 272,136 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. UBS Group initiated coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 price objective for the company. Oppenheimer lifted their price target on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 4th. Jefferies Financial Group initiated coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $41.00 price target on the stock. Barclays raised their price objective on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Finally, Royal Bank of Canada dropped their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, Nurix Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.